Journal article
LDL reduction: how low should we go and is it safe?
Current cardiology reports, Vol.10(6), pp.481-487
11/2008
DOI: 10.1007/s11886-008-0076-3
PMID: 18950559
Abstract
High-dose statin therapy or combination statin treatment is necessary for most patients to achieve aggressive low-density lipoprotein cholesterol goals. Adding ezetimibe or bile acid sequestrants appears unlikely to increase the risk of myopathy. Although the combination of niacin or fenofibrate with moderate-dose statins appears to be reasonably safe, the safety of combination with high-dose statins has yet to be determined. To enhance patient outcomes, attention must be paid to characteristics that predict muscle and hepatic statin toxicity when considering using high-dose statin or combination statin therapy.
Details
- Title: Subtitle
- LDL reduction: how low should we go and is it safe?
- Creators
- Jennifer G Robinson - Lipid Research Clinic, 200 Hawkins Drive SE 226 GH, Iowa City, IA 52242, USA. jennifer-g-robinson@uiowa.edu
- Resource Type
- Journal article
- Publication Details
- Current cardiology reports, Vol.10(6), pp.481-487
- Publisher
- United States
- DOI
- 10.1007/s11886-008-0076-3
- PMID
- 18950559
- ISSN
- 1523-3782
- eISSN
- 1534-3170
- Language
- English
- Date published
- 11/2008
- Academic Unit
- Epidemiology; Internal Medicine
- Record Identifier
- 9983996094502771
Metrics
24 Record Views